clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Cosgrove BD et al. | Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. | 2009 | Toxicol. Appl. Pharmacol. | pmid:19362101 |
| Peters TS | Do preclinical testing strategies help predict human hepatotoxic potentials? | 2005 | Toxicol Pathol | pmid:15805066 |
| De Lorenzi G et al. | Mycobacterium genavense Infection in a Domestic Ferret (Mustela putorius furo). | 2018 | Top Companion Anim Med | pmid:30502861 |
| Mukae H et al. | Low expression of T-cell co-stimulatory molecules in bone marrow-derived dendritic cells in a mouse model of chronic respiratory infection with Pseudomonas aeruginosa. | 2010 | Tohoku J. Exp. Med. | pmid:20046053 |
| Kaji C et al. | Antimicrobial effect of fluoroquinolones for the eradication of nontypeable Haemophilus influenzae isolates within biofilms. | 2008 | Tohoku J. Exp. Med. | pmid:18285669 |
| Walrave TR et al. | [Mania induced by antibiotic therapy]. | Tijdschr Psychiatr | pmid:27527887 | |
| Lygren I et al. | [Treatment of Helicobacter pylori infection]. | 1998 | Tidsskr. Nor. Laegeforen. | pmid:9889634 |
| Farup PG | [Treatment of Helicobacter pylori infection--results and experiences with an Internet-based collaboration trial]. | 2003 | Tidsskr. Nor. Laegeforen. | pmid:14714012 |
| Schweeger I et al. | Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers. | 2000 | Thromb. Res. | pmid:10704650 |
| van Ingen J et al. | Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. | 2009 | Thorax | pmid:19213773 |
| Andréjak C et al. | Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. | 2009 | Thorax | pmid:19052044 |
| Essilfie AT et al. | Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. | 2015 | Thorax | pmid:25746630 |
| Jenkins PA et al. | Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. | 2008 | Thorax | pmid:18250184 |
| Majoor CJ et al. | Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease. | 2004 | Thorax | pmid:15223876 |
| Spencer S and Jones PW | Time course of recovery of health status following an infective exacerbation of chronic bronchitis. | 2003 | Thorax | pmid:12832673 |
| Brusselle GG | Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases? | 2015 | Thorax | pmid:25870311 |
| Pinzani V et al. | [Occurrence of anterior uveitis in a HIV patient treated with rifabutin, ethambutol, clarithromycin]. | 1995 Sep-Oct | Therapie | pmid:8571297 |
| Bohr UR and Malfertheiner P | Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails. | 2009 | Therap Adv Gastroenterol | pmid:21180534 |
| Berning M et al. | Should quinolones come first in Helicobacter pylori therapy? | 2011 | Therap Adv Gastroenterol | pmid:21694812 |
| Mégraud F | The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. | 2012 | Therap Adv Gastroenterol | pmid:22423259 |
| Gisbert JP | Second-line rescue therapy of helicobacter pylori infection. | 2009 | Therap Adv Gastroenterol | pmid:21180581 |
| Krause M | [Resistance problems in gastrointestinal infections]. | 2002 | Ther Umsch | pmid:11851045 |
| Niioka T et al. | Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. | 2006 | Ther Drug Monit | pmid:16778714 |
| Kunicki PK and Sobieszczańska-Małek M | Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. | 2005 | Ther Drug Monit | pmid:15665756 |
| Zhou SF et al. | Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. | 2007 | Ther Drug Monit | pmid:18043468 |
| Zhanel GG et al. | Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. | 2006 | Ther Clin Risk Manag | pmid:18360582 |
| Nawarskas JJ and Snowden SS | Critical appraisal of ticagrelor in the management of acute coronary syndrome. | 2011 | Ther Clin Risk Manag | pmid:22241944 |
| Rafii F et al. | Effects of treatment with antimicrobial agents on the human colonic microflora. | 2008 | Ther Clin Risk Manag | pmid:19337440 |
| Chandwani A and Shuter J | Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. | 2008 | Ther Clin Risk Manag | pmid:19209283 |
| Zhou S et al. | Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. | 2005 | Ther Clin Risk Manag | pmid:18360537 |
| Hline SS et al. | Conivaptan: a step forward in the treatment of hyponatremia? | 2008 | Ther Clin Risk Manag | pmid:18728836 |
| Zong W et al. | The first case of cutaneous infection with Mycobacterium parascrofulaceum. | 2012 | Ther Clin Risk Manag | pmid:22930638 |
| Pace F et al. | A review of rabeprazole in the treatment of acid-related diseases. | 2007 | Ther Clin Risk Manag | pmid:18488081 |
| Oncü S | Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin. | 2007 | Ther Clin Risk Manag | pmid:18488076 |
| Duclos AJ et al. | Current treatment options in the management of chronic prostatitis. | 2007 | Ther Clin Risk Manag | pmid:18472971 |
| Ellsworth P | Fesoterodine for the treatment of urinary incontinence and overactive bladder. | 2009 | Ther Clin Risk Manag | pmid:19956551 |
| Carrie AG and Marrie TJ | Use of intravenous antibiotics for the treatment of community-acquired pneumonia in the emergency department. | 2005 | Ther Clin Risk Manag | pmid:18360543 |
| Goodman JJ and Martin SI | Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections. | 2012 | Ther Clin Risk Manag | pmid:22547933 |
| Werth S et al. | Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. | 2012 | Ther Clin Risk Manag | pmid:22547932 |
| Quan F et al. | Investigation of pulmonary infection pathogens in neurological intensive care unit. | 2011 | Ther Clin Risk Manag | pmid:21339939 |
| Neely M and Kovacs A | Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. | 2009 | Ther Clin Risk Manag | pmid:19707276 |
| Coeman M et al. | Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. | 2011 | Ther Adv Respir Dis | pmid:21890536 |
| Minushkin ON et al. | [Age and eradication treatment of duodenal ulcer]. | 2007 | Ter. Arkh. | pmid:17460963 |
| Vasil'ev IuV et al. | [Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. | 2002 | Ter. Arkh. | pmid:12360599 |
| Maev IV et al. | [Eradication therapy for Helicobacter pylori infection: review of world trends]. | 2014 | Ter. Arkh. | pmid:24779078 |
| Tsukanov VV et al. | [Helicobacter pylori eradication: current status]. | 2013 | Ter. Arkh. | pmid:23653944 |
| Maev IV et al. | [Experience in the use of losek (omeprazole) in gastroenterology]. | 2001 | Ter. Arkh. | pmid:11523419 |
| Konorev MR | [Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy]. | 2012 | Ter. Arkh. | pmid:23479993 |
| Kirika NV et al. | [Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer]. | 2004 | Ter. Arkh. | pmid:15106408 |
| Isakov VA et al. | [Results of an open multicenter study of the efficiency of one-week anti-helicobacter therapy using omeprazole, clarithromycin, and amoxicillin in patients with duodenal peptic ulcer]. | 2003 | Ter. Arkh. | pmid:14708448 |